Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chime Biologics Announces $190 Million Round for Wuhan CDMO Operations

publication date: Mar 26, 2021

Wuhan's Chime Biologics has commitments for a $190 million A+ round from institutional investors, which it will use to support its CDMO operations. One year ago, Chime was formed by spinning out the manufacturing operations from Taiwan's JHL Biotech after JHL was found guilty of violating Genentech's patents. The new financing was led by VMS Group and joined by Fidelity International and Panacea Venture. Last year, Chime Biologics completed its Series A round financing of $125 million. Chime's facilities are located in Wuhan BioLake Park. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital